Background: While systemic propranolol, β-blocker, is known for effective treatment for infantile hemangioma (IH), few study shows response rate of location and subtype to systemic propranolol treatment. HemangiolⓇ, formulation of oral propranolol, has been widely used since approval in Korea in 2015. Objectives: To evaluate the treatment response according to location and subtype of IH in systemic propranolol treatment. Methods: We evaluated 52 patients whose treatment was finished with hemangiolⓇ. Patients were prescribed dosage of 2mg/kg/day and clinical photo was taken every follow up visit including 3 months after end of treatment. We devided patients according to location and subtype. And photographs based visual scale was used to measure the response. Three investigators scored the treatment response and divided the patients into 5 response group. Results: 36(69%) patients had their IH in Head and neck(H&N) and 9 had in trunk, 7 had in extremities. And 47(90%) were focal and 5 were segmental type. 16(30%) were superficial and 7 were deep; 28 were mixed type. Overall, systemic propranolol showed favorable response. (mean=77.4%). Divided according to location(H&N, trunk, extremity), response rate was 77%, 80% and 75%, respectively. And according do subtype(superficial, mixed, deep type), response rate was 79%, 76% and 74%. No adverse event was observed except sleep disturbance (3.8%). Conclusion: These results suggest that systemic propranolol is safe and effective treatment of IH.